HomeAI · summaries
Storia in 3 fonti
‘Critically important’: Upfront sacituzumab govitecan combo benefits breast cancer subset
CHICAGO — New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus pembrolizumab should be “standard of care” for PD-L1-positive metastatic triple-negative breast cancer.The data, presented at ASCO Annual Meeting, showed that patients treated upfront with sacituzumab govitecan (Trodelvy, Gilead Sciences) plus
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
- ·
medpagetoday.com
More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer
ASCENT-04 analysis finds PFS2 advantage as an indicator of long-term clinical benefit
